Skip to main content

HEOR First Report

“While this dataset is still maturing, in this as-observed interim analysis of a real-world study, dupilumab demonstrated early and sustained improvement in AD flares, symptoms, and disea...
First Report
08/31/2020
Edan Stanley
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS, Pharmacy Solutions Coordinator, Conduent, discusses a recent study in which she and her colleagues measured the cost effectiveness and utilizations rates associated with emicizumab-kxwh treatment for patients with...
Karen Powell, PharmD, MS,...
08/31/2020
First Report Managed Care
Recent data showing high persistence rates for dupilumab therapy in patients with atopic dermatitis suggest that the treatment is well-tolerated and effective.
“In this analysis, emicizumab-kxwh therapy was associated with a decrease in the cost of HEM medications and cost and utilization of medical services,” explained researchers.
When patients with gBRCA1/2mut HER2− advanced breast cancer switched from olaparib to talazoparib, a reduction in costs for US commercial health plans was observed.
Recent data shows that ixekizumab limits out-of-pocket spending for psoriatic arthritis treatment, despite associated higher pharmacy costs.
According to a study focused on real world data, adults with severe eosinophilic asthma experienced symptomatic improvements and decreased health care resource utilization when treated wi...